Evidence map›Paper›PMID 19480662›Full record

ArticleBMC biochemistry2009

A novel human NatA Nalpha-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1).

Thomas Arnesen, Darina Gromyko, Diane Kagabo, Matthew J Betts, Kristian K Starheim, Jan Erik Varhaug, Dave Anderson, Johan R Lillehaug

Open access · bronzeAbstract read
In one paragraph

Article in BMC biochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Synthesis of Recombinant Human Hemoglobin With NHCurrent protocols in protein science · 2020
    Article
  11. Article
  12. Article
  13. ARD1/NAA10 acetylation in prostate cancer.Experimental & molecular medicine · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 4 countries.

Thomas ArnesenDepartment of Molecular Biology, University of Bergen, N-5020 Bergen, Norway. Thomas.Arnesen@mbi.uib.no
Darina Gromyko
Diane Kagabo
Matthew J Betts
Kristian K Starheim
Jan Erik Varhaug
Dave Anderson
Johan R Lillehaug
University of Bergen · NOEuropean Bioinformatics Institute · GBOregon Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProtein acetylation is among the most common protein modifications. The two major types are post-translational Nepsilon-lysine acetylation catalyzed by KATs (Lysine acetyltransferases, previously named HATs (histone acetyltransferases) and co-translational Nalpha-terminal acetylation catalyzed by NATs (N-terminal acetyltransferases). The major NAT complex in yeast, NatA, is composed of the catalytic subunit Naa10p (N alpha acetyltransferase 10 protein) (Ard1p) and the auxiliary subunit Naa15p (Nat1p). The NatA complex potentially acetylates Ser-, Ala-, Thr-, Gly-, Val- and Cys- N-termini after Met-cleavage. In humans, the homologues hNaa15p (hNat1) and hNaa10p (hArd1) were demonstrated to form a stable ribosome associated NAT complex acetylating NatA type N-termini in vitro and in vivo.

resultsWe here describe a novel human protein, hNaa16p (hNat2), with 70% sequence identity to hNaa15p (hNat1). The gene encoding hNaa16p originates from an early vertebrate duplication event from the common ancestor of hNAA15 and hNAA16. Immunoprecipitation coupled to mass spectrometry identified both endogenous hNaa15p and hNaa16p as distinct interaction partners of hNaa10p in HEK293 cells, thus demonstrating the presence of both hNaa15p-hNaa10p and hNaa16p-hNaa10p complexes. The hNaa16p-hNaa10p complex acetylates NatA type N-termini in vitro. hNaa16p is ribosome associated, supporting its potential role in cotranslational Nalpha-terminal acetylation. hNAA16 is expressed in a variety of human cell lines, but is generally less abundant as compared to hNAA15. Specific knockdown of hNAA16 induces cell death, suggesting an essential role for hNaa16p in human cells.

conclusionAt least two distinct NatA protein Nalpha-terminal acetyltransferases coexist in human cells potentially creating a more complex and flexible system for Nalpha-terminal acetylation as compared to lower eukaryotes.

Indexed as

AcetylationAcetyltransferasesAmino Acid SequenceArylamine N-AcetyltransferaseCell DeathCell Line, TumorEvolution, MolecularHumansIsoenzymesMolecular Sequence DataMultienzyme ComplexesN-Terminal Acetyltransferase EN-Terminal AcetyltransferasesPeptidesPhylogenyProtein Processing, Post-TranslationalAcetyltransferasesArylamine N-AcetyltransferaseIsoenzymesMultienzyme ComplexesN-acetyltransferase 1NAT10 protein, humanNAT2 protein, humanN-Terminal Acetyltransferase EN-Terminal AcetyltransferasesPeptides

Identifiers

PMID19480662
PMCPMC2695478
OpenAlexW2075971798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.